Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Cohort begins May 4, 2020
Filter by Type:
Filter by Topic:
A Pharm-Olam case study of a Phase I/II pediatric Respiratory Distress Syndrome neonate study with a gestational age between 27 and 33 weeks.
2 min. Read
In this Phase III study, Pharm-Olam partnered with a progressive sponsor company to assist in finding a better solution for suffering with ...
3 min. read
Pharm-Olam provided a complete enrollment solution for the management and data submission of this Acute Bacterial Skin and Skin Structure ...
A Pharm-Olam overview of Allergic Rhinitis based on two decades of study experience.
2 min. read
Watch the webinar and learn how clinical research is shifting from developing blockbuster drugs for everyone, to more targeted therapies that ...
60 min. watch
Join us for an in-depth discussion on GDPR implementation in Clinical Trials. We will discuss strategies, best practices and industry status. ...
We'll only send you one email a month featuring our best content from the month before.